Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Multicenter, Randomized, Double Blind Study of Clinical Outcomes, Tolerability, and Safety of 2 Doses of Oral Pantoprazole In Pediatric Participants Aged 1 to 11 Years and 12 to 17 Years Who Require Maintenance Therapy for Healed Erosive Esophagitis

Next Previous
Trial Profile

An Exploratory, Multicenter, Randomized, Double Blind Study of Clinical Outcomes, Tolerability, and Safety of 2 Doses of Oral Pantoprazole In Pediatric Participants Aged 1 to 11 Years and 12 to 17 Years Who Require Maintenance Therapy for Healed Erosive Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pantoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 24 Dec 2025 Actual primary completion date is 16 Dec 2025.
  • 24 Dec 2025 Status changed from active, no longer recruiting to completed.
  • 15 Jun 2025 Planned End Date changed from 9 Dec 2027 to 9 May 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top